Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

Inclusion Criteria

• •1\. 22-70 years.
• •2\. Subject qualifies to receive TMS Therapy with the NeuroStar Advanced Therapy System to treat Major Depressive Disorder (MDD) per current FDA-cleared treatment guidelines as evaluated by the treating physician.
• •3\. Subject has MDD diagnosis according to applicable DSM-IV, DSM-IV-TR, DSM-V, ICD-9, or ICD-10 criteria.
• •4\. Subject failed to respond to at least one prior anti-depressant medication. 5. Subject consented to receive TMS Therapy to treat MDD with his or her physician independent of potential participation in this clinical study.
• •6\. Subject must agree not to take analgesic pain medication(s) within 8 hours prior to TMS therapy sessions.
• •7\. Subject provides written consent to take part in the study.